Pneumology - Original Articles
13 October 2025
Early Access
https://doi.org/10.4081/monaldi.2025.3468

The diagnostic yield of the survivin gene in patients with lung cancer

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Lung cancer, bronchial aspirate, survivin gene
0
Views
0
Downloads

Authors

Azza Farag Said
azza.sayed@mu.edu.eg
Chest Diseases Department, Faculty of Medicine, Minia University, Minia City, Egypt.
Hager Yehia Mohamed
Chest Diseases Department, Faculty of Medicine, Minia University, Minia City, Egypt.
Amel Mahmoud Kamaleldin
Clinical Pathology Department, Faculty of Medicine, Minia University, Minia City, Egypt.
Shady Elia Anis
Anatomic Pathology Department, Faculty of Medicine, Cairo University, Cairo City, Egypt.
Zainab Hassan Saeed
Chest Diseases Department, Faculty of Medicine, Minia University, Minia City, Egypt.

It has been discovered that many solid tumors express the survivin gene, particularly in tissue samples. On the other hand, limited data exist on the significance of the survivin gene in bronchial aspirates from lung cancer patients. The current study was designed to evaluate the levels of the survivin gene in lung cancer patients and correlate them with other clinical features. The study population consisted of 58 patients with lung cancer. A total of 25 patients with non-malignant lung diseases were used as a comparable group. We used real-time quantitative reverse transcription polymerase chain reaction to assess survivin gene level in bronchial aspirate during bronchoscopy from individuals with lung cancer, as well as those with benign lung diseases. Cases with lung cancer had bronchial aspirates with a substantially greater survivin gene level (3.7±1.8) compared to individuals with benign lung illnesses (1.1±0.9) (p=0.0001). The lung cancer diagnosis had a sensitivity of 74.14% and a specificity of 96% when 2.4 of the survivin gene was used as the cutoff value. The levels of the survivin gene in lung cancer patients were significantly positively correlated with both age and performance status, with p values of 0.012 and 0.0001, respectively. Nonetheless, there was a negative connection between the survivin gene level and the length of symptoms as well as the survival time in months, with p-values of 0.027 and 0.001, respectively. As a molecular marker, survivin gene identification in bronchial aspirate has both diagnostic and prognostic significance for lung cancer.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Su Z, Yang Z, Xu Y, et al. Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer 2015;14:48. DOI: https://doi.org/10.1186/s12943-015-0321-5
Mobahat M, Narendran A, Riabowol K. Survivin as a preferential target for cancer therapy. Int J Mol Sci 2014; 15: 2494-516. DOI: https://doi.org/10.3390/ijms15022494
Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000;6:1796-803.
Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001;7:542-7. DOI: https://doi.org/10.1016/S1471-4914(01)02243-2
Wu YK, Chen KT, Kuo YB, et al. Quantitative detection of survivin in malignant pleural effusion for the diagnosis and prognosis of lung cancer. Cancer Lett 2009;273:331-5. DOI: https://doi.org/10.1016/j.canlet.2008.08.023
Roth K, Hardie JA, Andreassen AH, et al. Predictors of diagnostic yield in bronchoscopy: a retrospective cohort study comparing different combinations of sampling techniques. BMC Pulm Med 2008;8:2. DOI: https://doi.org/10.1186/1471-2466-8-2
Hirsch FR, Merrick DT, Franklin WA. Role of biomarker for early detection of lung cancer and chemoprevention. Eur Respir J 2009;19:1151-8. DOI: https://doi.org/10.1183/09031936.02.00294102
Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-51. DOI: https://doi.org/10.1016/0895-4356(94)90129-5
Du Rand IA, Blaikley J, Booton R, et al. British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. Thorax 2013;68:i1-44. DOI: https://doi.org/10.1136/thoraxjnl-2013-203618
Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC lung cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol 2015;10:990-1003. DOI: https://doi.org/10.1097/JTO.0000000000000559
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55. DOI: https://doi.org/10.1097/00000421-198212000-00014
Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-6. DOI: https://doi.org/10.1038/35037710
Ward TH, Cummings J, Dean E, et al. Biomarkers of apoptosis. Br J Cancer 2008;99:841-6. DOI: https://doi.org/10.1038/sj.bjc.6604519
Li J, Chen P, Li XQ, et al. Elevated levels of survivin and livin mRNA in bronchial aspirates as markers to support the diagnosis of lung cancer. Int J Cancer 2013;132:1098-104. DOI: https://doi.org/10.1002/ijc.27757
Falleni M, Pellegrini C, Marchetti A, et al. Survivin gene expression in early‐stage non‐small cell lung cancer. J Pathol 2003;200:620-6. DOI: https://doi.org/10.1002/path.1388
Xiu Y, Sun B, Jiang Y, et al. Diagnostic value of the survivin autoantibody in four types of malignancies. Genet Test Mol Biomarkers 2018;22:384-9. DOI: https://doi.org/10.1089/gtmb.2017.0278
Hassan MH, Abuhamdah S, Abdel-Bary M, et al. Circulating and local nuclear expression of surviving and fibulin-3 genes in discriminating benign from malignant respiratory diseases: correlation analysis. Biosci Rep 2021;41:BSR20203097. DOI: https://doi.org/10.1042/BSR20203097
Duan L, Hu X, Jin Y, et al . Survivin protein expression is involved in the progression of non-small cell lung cancer in Asians: a meta-analysis. BMC Cancer 2016;16:276. DOI: https://doi.org/10.1186/s12885-016-2304-3
Yano, Y, Otsuka T, Hirano H, et al. Nuclear survivin expression in small cell lung cancer. Anticancer Res 2015;35:2935-9.
Al-khalaf HH , Aboussekhra A . Survivin expression increases during aging and enhances the resistance of aged human fibroblasts to gentoxic stress. Age 2013;35:549-62. DOI: https://doi.org/10.1007/s11357-011-9378-2
Karczmarek-Borowska B, Filip A, Wojcierowski J, et al. Survivin antiapoptotic gene expression as a prognostic factor in non-small cell lung cancer: in situ hybridization study. Folia Histochem Cytobiol 2005;43:237-42.
Lu B, Gonzalez A, Massion P, et al. Nuclear survivin as a biomarker for non-small-cell lung cancer. Br J Cancer 2004;91:537-40. DOI: https://doi.org/10.1038/sj.bjc.6602027

Ethics approval

The study protocol was approved by the Research Ethics Committee of Faculty of Medicine, Minia University, Egypt (21/11/2017).

How to Cite



“The Diagnostic Yield of the Survivin Gene in Patients With Lung Cancer”. 2025. Monaldi Archives for Chest Disease, October. https://doi.org/10.4081/monaldi.2025.3468.
Copyright (c) 2025 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.